	mus.	
mORK1	MESPIQIFRGDPGPTCSPSACLLPNSSSW::::::FPNWAESDSNGSVGSEDQQLESAHISPAIPVIITAV	-
mORD1	ME::::::::::!VPSAPAFIOCONTINU CDARD CARDON * *     ***	
	ME::::::::::LVPSARAELQSSPLVNLSDAFPSAFPSAGANASGSPGARSASSL:::ALAIAITALY TM2	
mORK1	TO THE VIEW VII A LIKELY WALLAND A LANDA TO THE TOTAL TO THE TANK	
mORD1	SAVCAVGLIGNVLVMFGIVRYTKLKTATNIYIFNLALADALATSTLPFQSAKYLMETWPFGELLCKAVLSID	
morki	YYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPLKAKIINICIWLLASSVGISAIVLGGTKVREDVDVIEC	
	10000000000000000000000000000000000000	
mORD1	YYNMFTSIFTLTMMSVDRYTAVCUDVVAIDEDTDAVAVT	
	YYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPAKAKLINICIWVLASGVGVPIMVMAVTQPRDGAVV::C	
mORK1	SLQFPDDEYSWWDLFMKICVFVFAFVIPVLIIIVCYTLMILRLKSVRLLSGSREKDRNLRRITKLVLVVVAV	
	MI.OFP.CP.CW. VIIDTIMY COME TO THE COME TO	282
mORD1	MLOFPSPSW: YWDTUTKICUFI FARMURTI TITUUUNGAA	
	MLQFPSPSW:YWDTVTKICVFLFAFVVPILIITVCYGLMLLRLRSVRLLSGSKEKDRSLRRITRMVLVVVGA	269
.morrit	FIICWTPIHIFILVEALGSTSHSTAALSSYY: FCIALGYTNSSLNPVLYAFLDENFKRCFRDFCFPIKMRME	353
mORD1	FVVCWAPIHIFVIVWTLVDINRRDPLVVAALHLCIALGYANSSLNPVLYAFLDENFKRCFRQLCRTPCGRQE	_
	THE LIBERT RRCF RQLCRTPCGRQE	341
mORK1	RQSTNRVRNTVQDP::::ASMRDVGGMNKPV - 380 (SEQ ID NO:2)	
	* * * *	
ומפסת	PGCI PBB POATT PERIOD CONTROL OF THE ACTION AND ACTION ACTION AND ACTION AND ACTION AND ACTION AND ACTION ACTION ACTION AND ACTION ACTIO	
T	PGSLRRPRQATTRERVTACTPSDGPGGGAAA - 372 (SEQ ID NO:4)	






FIG. 2a






FIG. 2b

1	AAGAAGCAAAATCAGTAATCCAAAGGCTATCACAAA	CACATTCACCTTATGGGGTTTGAC
61	TTGAAAATGGAGGGAAATGCTATTGTTTCTTTCTT	TyrThrLysMetLysThrAla TTAGATACACAAAGATGAAGACAG
121	ThrAsnIleTyrIlePheAsnLeuAlaLeuAlaA CAACCAACATTTACATATTTAACCTGGCTTTGGCAG	spAlaLeuValThrThrThrMetPro ATGCTTTAGTTACTACAACCATGC
181	PheGlnSerThrValTyrLeuMetAsnSerTrpP CCTTTCAGAGTACGGTCTACTTGATGAATTCCTGGC	roPheGlyAspValLeuCysLysIle CTTTTGGGGATGTGCTGTGCAAGA
241	VallleSerlleAspTyrTyrAsnMetPheThrS TAGTAATTTCCATTGATTACTACAACATGTTCACCA	erllePheThrLeuThrMetMetSer GCATCTTCACCTTGACCATGATGA
301	ValAspArgTyrIleAlaValCysHisProValL GCGTGGACCGCTACATTGCCGTGTGCCACCCCGTGA	ysAlaLeuAspPheArgThrProLeu AGGCTTTGGACTTCCGCACACCCT
361	LysAlaLysIleIleAsnIleCysIleTrpLeuLorGAAGGCAAAGATCATCAATATCTGCATCTGGCTGC	euSerSerSerValGlyIleSerAla TGTCGTCATCTGTTGGCATCTCTG
421	<pre>IleValLeuGlyGlyThrLysValArgGluA CAATAGTCCTTGGAGGCACCAAAGTCAGGGAAGGT:</pre>	::::::::::::::::::::::::::::::::::::::
481	spValAspValIleC GGTTTTTATTGCCCTCCTCCAGACGTCGATGTCATTC	luCysCysLeuGlnPheProAsp AGTGCTGCTTGCAGTTCCCAGAT
541	AspAspTyrSerTrpTrpAspLeuPheMetLysIleC GATGACTACTCCTGGTGGGACCTCTTCATGAAGATCT	ysValPhellePheAlaPheVal GCGTCTTCATCTTTGCCTTCGTG
601	IleProValLeuIleIleIleValCysTyrThrLeuM ATCCCTGTCCTCATCATCATCGTCTGCTACACCCTGA	etlleLeuArgLeuLysNNNVal TGATCCTGCGTCTCAAGANNGTC
661	ArgLeuLeuSerGlySerArgGluLysAspNNNAsnL CGGCTCCTTTCTGGCTCCCGAGAGAAAGATNNCAACC	euArgArgIleThrArgLeuVal TGCGTAGGATCACCAGACTGGTC
721	LeuValValValAlaValPheValValCysTrpThrP CTGGTGGTGGTGGCAGTCTTCGTCGTCTGCTGGACTC	rolleHisllePhelleLeuVal CCATTCACATATTCATCCTGGTG
781	GluAlaLeuGlySerThrSerHisSerThrAlaAlaL GAGGCTCTGGGGAGCACCTCCCACAGCACAGCTGCTC	euSerSerTyrTyrPheCyslle TCTCCAGCTATTACTTCTGCATC
841	AlaLeuGlyTyrThrAsnSerSerLeuAsnProlleL GCCTTAGGCTATACCAACAGTAGCCTGAATCCCATTC	euTyrAlaPheLeuAspGluAsn FCTACGCCTTTCTTGATGAAAAC
901	PheLysArgCysPheArgAspPheCysPheProLeuL TTCAAGCGGTGTTTCCGGGACTTCTGCTTTCCACTGA	ysMetNNNMetGluArgNNNSer AGATGAGNATGGAGCGCNAGAGC
961	ThrSerArgValArgAsnThrValGlnAspProAlaTy ACTAGCAGAGTCCGAAATACAGTTCAGGATCCTGCTTA	rLeuArgGluIleAspGlyMet ACCTGAGGGAGATCGATGGGATG
1021	MetAsnLysProValop ATGAATAAACCAGTATGACTAGTCGTGGA	(SEQ ID NO:12) (SEQ ID NO:11)

Met Glu Ser Pro Ile Gln Ile Phe Arg Gly Asp Pro Gly Pro Thr Cys Ser Pro Ser Ala Cys Leu Leu Pro Asn Ser Ser Trp Phe Pro Asn Trp Ala Glu Ser Asp Ser Asn Gly Ser Val Gly Ser Glu Asp Gln Gln Leu Glu Ser Ala His Ile Ser Pro Ala Ile Pro Val Ile Ile Thr Ala Val Tyr Ser Val Val Phe Val Val Gly Leu Val Gly Asn Ser Leu Val HUMAN Tyr Thr Lys Met Lys Thr Ala Thr Asn Ile MOUSE Met Phe Val Ile Ile Arg Tyr Thr Lys Met Lys Thr Ala Thr Asn Ile 90 HUMAN Tyr Ile Phe Asn Leu Ala Leu Ala Asp Ala Leu Val Thr Thr Met MOUSE Tyr Ile Phe Asn Leu Ala Leu Ala Asp Ala Leu Val Thr Thr Met 100 105 110 HUMAN Pro Phe Gln Ser Thr Val Tyr Leu Met Asn Ser Trp Pro Phe Gly Asp MOUSE Pro Phe Gln Ser Ala Val Tyr Leu Met Asn Ser Trp Pro Phe Gly Asp 115 120 HUMAN Val Leu Cys Lys Ile Val Ile Ser Ile Asp Tyr Tyr Asn Met Phe Thr MOUSE Val Leu Cys Lys Ile Val Ile Ser Ile Asp Tyr Tyr Asn Met Phe Thr 135 Ser Ile Phe Thr Leu Thr Met Met Ser Val Asp Arg Tyr Ile Ala Val HUMAN MOUSE Ser Ile Phe Thr Leu Thr Met Met Ser Val Asp Arg Tyr Ile Ala Val 150 Cys His Pro Val Lys Ala Leu Asp Phe Arg Thr Pro Leu Lys Ala Lys Cys His Pro Val Lys Ala Leu Asp Phe Arg Thr Pro Leu Lys Ala Lys HUMAN MOUSE Ile Ile Asn Ile Cys Ile Trp Leu Leu Ser Ser Ser Val Gly Ile Ser Ile Ile Asn Ile Cys Ile Trp Leu Leu Ala Ser Ser Val Gly Ile Ser HUMAN MOUSE Ala Ile Val Leu Gly Gly Thr Lys Val Arg Glu Asp Val Asp Val Ile Ala Ile Val Leu Gly Gly Thr Lys Val Arg Glu Asp Val Asp Val Ile HUMAN MOUSE Glu Cys Cys Leu Gln Phe Pro Asp Asp Asp Tyr Ser Trp Trp Asp Leu Glu Cys Ser Leu Gln Phe Pro Asp Asp Glu Tyr Ser Trp Trp Asp Leu HUMAN MOUSE HUMAN Phe Met Lys Ile Cys Val Phe Ile Phe Ala Phe Val Ile Pro Val Leu Phe Met Lys Ile Cys Val Phe Val Phe Ala Phe Val Ile Pro Val Leu MOUSE 225 Ile Ile Ile Val Cys Tyr Thr Leu Met Ile Leu Arg Leu Lys NNN Val Ile Ile Ile Val Cys Tyr Thr Leu Met Ile Leu Arg Leu Lys Ser Val HUMAN MOUSE

					<b>N</b>													
HUMAN MOUSE	Arg Arg	Leu Leu	Leu Leu	Ser 260	Gly	Ser Ser	Arg Arg	Glu Glu	Lys Lys 265	Asp	NNN Arg	As. Asn	Leu Leu	Arg Arg 270	Arg Arg	Ile   } Ile	455€	<b>83</b>
HUMAN MOUSE	Thr Thr	Arg Lys	Leu Leu 275	Val Val	Leu Leu	Val Val	Val Val	Val Val 280	Ala Ala	Val Val	Phe Phe	Val Íle	Val Ile 285	Сув Сув	Trp Trp	Thr Thr		
HUMAN MOUSE	Pro Pro	Ile Ile 290	His His	Ile Ile	Phe Phe	Ile Ile	Leu Leu 295	Val Val	Glu Glu	Ala Ala	Leu Leu	Gly Gly 300	Ser Ser	Thr Thr	Ser Ser	His His		
HUMAN MOUSE	Ser Ser 305	Thr Thr	Ala Ala	Ala Ala	Leu Leu	Ser Ser 310	Ser Ser	Tyr Tyr	Tyr Tyr	Phe Phe	Сув Сув 315	Ile Ile	Ala Ala	Leu Leu	Gly Gly	Tyr Tyr 320		
HUMAN MOUSE	Thr Thr	Asn Asn	Ser Ser	Ser Ser	Leu Leu 325	Asn Asn	Pro Pro	Ile Val	Leu Leu	Tyr Tyr 330	Ala Ala	Phe Phe	Leu Leu	Asp Asp	Glu Glu 335	Asn Asn		
HUMAN MOUSE	Phe Phe	Lys Lys	Arg Arg	Сув Сув 340	Phe Phe	Arg Arg	Asp	Phe Phe	Сув Сув 345	Phe Phe	Pro Pro	Leu Ile	Lys Lys	Met Met 350	NNN Arg	Met Met		
HUMAN MOUSE	Glu Glu	Arg Arg	NNN Gln 355	Ser Ser	Thr Thr	Ser Asn	Arg Arg	Val Val 360	Arg Arg	Asn Asn	Thr Thr	Val Val	Gln Gln 365	Asp	Pro Pro	Ala Ala		
HUMAN MOUSE	Tyr	Leu Ser	Arg Met 370	Glu Arg	Ile Asp	Asp Val	Gly Gly	Met Gly 375	Met Met	Asn Asn	rys rys	Pro Pro	Val Val 380			D NO:12 D NO:2)		




FIG. 5b




FIG. 5c





FIG. 5d

BOUND fmol/mg protein



BOUND/FREE
(finol/mg profein/mM)

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

1000

10

FIG. 5f BOUND finoling proteins




FIG. 6a




FIG. 6b






FIG. 7a




FIG. 7c




FIG. 7b




FIG. 7d






FIG. 8

14/25




FIG. 9a






FIG. 9b

16/25




FIG. 10a




FIG. 10b

1.0

0.5

0.0

1.5

2.0

2.5

3.0

3.5

4.0




FIG. 12a

FIG. 12b

FIG. 12c





FIG. 13








FIG. 15



Percent forskolin-stimulated

FIG. 16



(% CONTROL)

RADIOLIGAND BINDING

FIG. 17



FIG. 18